Bud BilanichSuccess Coach
Matthew DurhamOmnidynamic Marketing
Matt TurnerPatient Affordability
Amy GilesIncreasing Engagement
Brenda SnowAuthentic Patient Voice
Stacey GandlerBrand Nourishment
Daniel SontupeMarket Access
Pat PurcellMeeting Engagement
Suma Ramadas, PhDMedical Affairs
Paul TheisenPatient Acquisition
David LinetskyPoint-of-Care Marketing
Joey CohenMedication Adherence
Frank BurrellScientific Storytelling
Liz KaneImpactful Strategy
6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients Well-tolerated with ...
Iclaprim met the primary endpointIclaprim was well tolerated in the study Additional data from ...
Username
Email
Password
Confirm Password
Remember Me
Username or Email